November 18, 2026
AABB released a new toolkit to help blood collection facilities implement FDA’s final guidance on reducing the risk of transfusion-transmitted hepatitis B virus (HBV).
As reported on Nov. 4, the guidance finalizes the July 2025 draft guidance without changes and consolidates FDA’s HBV recommendations into a single document. The final guidance also recommends blood collection facilities discontinue HBsAg testing of whole blood and blood components when each donation is tested for anti-HBc and for HBV DNA by NAT using FDA-licensed donor screening tests. The recommendations for source plasma are unchanged.
AABB’s new toolkit summarizes the key changes in the guidance and FDA’s rationale. It also presents the guidance’s recommendations in three flowcharts: donation testing and donor deferral; requalification of donors deferred because of reactive HBV test results; and product management, retrieval and quarantine, and notification of consignees. Each step cites the applicable regulation and guidance section, so users can quickly refer back to the source.
The toolkit also covers labeling changes, including updates to the Circular of Information when HBsAg testing is discontinued, and how to report changes to FDA. Licensed establishments that discontinue HBsAg testing, make conforming changes to donor requalification, or revise their Circular of Information consistent with the guidance must report these changes in an annual report under 21 CFR 601.12(d). Unlicensed establishments do not need to report these changes, nor do establishments that continue HBsAg testing without making other changes. Implementing an HBV testing strategy or other procedures other than as recommended in the guidance is considered a major change, and licensed establishments must submit a prior approval supplement under 21 CFR 601.12(b).
FDA Recommended Update to the Circular
The AABB Circular of Information Task Force worked with FDA to develop language addressing blood products remaining in inventory that were tested for HBsAg. FDA recommends that establishments add the following statements to the blank pages at the beginning of their Circular of Information at the time HBsAg testing is discontinued:
“Hepatitis B virus testing results:
Blood and blood components collected before [MM/DD/YYYY] were tested for HBsAg, anti-HBc and HBV DNA by NAT and found nonreactive.
Blood and blood components collected on or after [MM/DD/YYYY] were tested for anti-HBc and HBV DNA by NAT and found nonreactive.”
AABB has confirmed with FDA that inclusion of the two statements above meets the recommendation in Section IV.D.1, Labeling, of the November 2026 HBV Guidance to update the Circular of Information under 21 CFR 606.122(h).
This language is included in the toolkit and is also available on the AABB Circular of Information webpage.
Members with additional questions are invited to contact regulatory@aabb.org.